Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05125809 · ClinicalTrials.gov registry record · Phase 2
Setrusumab vs Placebo for Osteogenesis Imperfecta
A Phase 2 study of Osteogenesis Imperfecta, sponsored by Ultragenyx Pharmaceutical.
- Active
- Registry status
- Phase 2
- Development phase
- 183
- Enrollment target
- 20
- Study locations
NCT05125809 is a Phase 2 study of Osteogenesis Imperfecta that is active but no longer recruiting, run by Ultragenyx Pharmaceutical. The registered enrollment target is 183 participants, above the 147-participant average among 13 other Osteogenesis Imperfecta trials with a reported enrollment target (24% higher). The trial reports 20 study locations across 18 states.
The verdict
NCT05125809, a Phase 2 study of Osteogenesis Imperfecta, is active but no longer recruiting, sponsored by Ultragenyx Pharmaceutical.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 183 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives of the study are to identify a setrusumab dosing strategy in participants with OI and to evaluate the effect of setrusumab vs placebo on reduction in fracture rate.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Setrusumab
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- Shriners Hospital for Children - Northern California - Sacramento
Connecticut
- Connecticut Children's Medical Center - Hartford
- Yale New Haven Hospital - New Haven
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- Children's Hospital Colorado - Aurora
Delaware
- Nemours/ Alfred i. duPoint Hospital for Children - Wilmington
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- University of South Florida - Tampa
Illinois
- Shriners Hospitals for Children - Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2022-02-21 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05125809
The ClinicalTrials.gov registry entry for NCT05125809 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 147-participant average among 13 other Osteogenesis Imperfecta trials with a reported enrollment target (24% higher). The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteogenesis Imperfecta appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05125809 reports 20 study locations spanning 18 distinct geographic areas - top geographies include California, Connecticut, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05125809 about?
NCT05125809 is a clinical study titled "Setrusumab vs Placebo for Osteogenesis Imperfecta". The primary objectives of the study are to identify a setrusumab dosing strategy in participants with OI and to evaluate the effect of setrusumab vs placebo on reduction in fracture rate.
What is the current status of trial NCT05125809?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 183 participants. The study started on 2022-02-21. Estimated completion is 2027-04.
What conditions does trial NCT05125809 study?
This clinical trial studies the following conditions: Osteogenesis Imperfecta.
What interventions are being tested in trial NCT05125809?
The interventions under investigation include: Placebo (OTHER), Setrusumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05125809?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05125809 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteogenesis Imperfecta
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta
COMPLETED · Phase 2
-
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
RECRUITING · Phase 3
-
Effects of Bisphosphonates on OI-Related Hearing Loss
RECRUITING · Phase 4
-
BBD Longitudinal Study of Osteogenesis Imperfecta
RECRUITING
-
Urinary Biomarkers of OI Pathobiology
ACTIVE NOT RECRUITING
-
Clear Aligners for the Treatment of Dental Malocclusion in OI
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.